Cargando…
Identification of a recombinant equine coronavirus in donkey, China
Equine coronavirus (ECoV) was first identified in the USA and has been previously described in several countries. In order to test the presence of ECoV in China, we collected 51 small intestinal samples from donkey foals with diarrhoea from a donkey farm in Shandong Province, China between August 20...
Autores principales: | Qi, Peng-Fei, Gao, Xing-Yi, Ji, Jing-Kai, Zhang, Yan, Yang, Shao-Hua, Cheng, Kai-Hui, Cui, Ning, Zhu, Man-Ling, Hu, Tao, Dong, Xuan, Yan, Bin, Wang, Chang-Fa, Yang, Hong-Jun, Shi, Wei-Feng, Zhang, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986280/ https://www.ncbi.nlm.nih.gov/pubmed/35311478 http://dx.doi.org/10.1080/22221751.2022.2056522 |
Ejemplares similares
-
Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants
por: Zhao, Zhuxiang, et al.
Publicado: (2022) -
Two novel human coronavirus OC43 genotypes circulating in hospitalized children with pneumonia in China
por: Zhang, Zhaoyong, et al.
Publicado: (2022) -
An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen
por: Wang, Xinling, et al.
Publicado: (2023) -
Assessment and sero-diagnosis for coronaviruses with risk of human spillover
por: Zheng, Xiao-Shuang, et al.
Publicado: (2023) -
Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial
por: Wang, Xuan-Yi, et al.
Publicado: (2022)